Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    19451433 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Condition: Life Threatening Diseases
Intervention: Drug: Imatinib mesylate
2 Completed Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
Conditions: Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Intervention: Drug: imatinib mesylate

Study has passed its completion date and status has not been verified in more than two years.